Chiara Soldati

Chiara Soldati

Auto-generated profile, based on publicly available information

Chiara Soldati

Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli Naples Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
CSChiara Soldati
Chiara Soldati
ILIrene Lopez‐Fabuel
Irene Lopez‐Fabuel
LWLuca G Wanderlingh
Luca G Wanderlingh
Marina Garcia-MaciaMarina Garcia-Macia
Marina Garcia-Macia
JMJlenia Monfregola
Jlenia Monfregola
Diego L. MedinaDiego L. Medina
Diego L. Medina
Batten diseases (BDs) are a group of lysosomal storage disorders characterized by seizure, visual loss, and cognitive and motor deterioration. We discovered increased levels of globotriaosylceramide (Gb3) in cellular and murine models of CLN3 and CLN7 diseases and used fluorescent‐conjugated bacterial toxins to label Gb3 to develop a cell‐based high content imaging (HCI) screening assay for the repurposing of FDA‐approved compounds able to reduce this accumulation within BD cells. We found that tamoxifen reduced the lysosomal accumulation of Gb3 in CLN3 and CLN7 cell models, including neuronal progenitor cells (NPCs) from CLN7 patient‐derived induced pluripotent stem cells (iPSC). Here, tamoxifen exerts its action through a mechanism that involves activation of the transcription factor EB (TFEB), a master gene of lysosomal function and autophagy. In vivo administration of tamoxifen to the CLN7 Δex2 mouse model reduced the accumulation of Gb3 and SCMAS, decreased neuroinflammation, and improved motor coordination. These data strongly suggest that tamoxifen may be a suitable drug to treat some types of Batten disease.

1 November 2020 in iScience
Verified
Journal Article
Open access
PCPablo S. Contreras
Pablo S. Contreras
PTPablo J Tapia
Pablo J Tapia
LGLila González-Hódar
Lila González-Hódar
IPIvana Peluso
Ivana Peluso
CSChiara Soldati
Chiara Soldati
Silvana ZanlungoSilvana Zanlungo
Silvana Zanlungo
The transcription factor EB (TFEB) has emerged as a master regulator of lysosomal biogenesis, exocytosis, and autophagy, promoting the clearance of substrates stored in cells. c-Abl is a tyrosine kinase that participates in cellular signaling in physiological and pathophysiological conditions. In this study, we explored the connection between c-Abl and TFEB. Here, we show that under pharmacological and genetic c-Abl inhibition, TFEB translocates into the nucleus promoting the expression of its target genes independently of its well-known regulator, mammalian target of rapamycin complex 1. Active c-Abl induces TFEB phosphorylation on tyrosine and the inhibition of this kinase promotes lysosomal biogenesis, autophagy, and exocytosis. c-Abl inhibition in Niemann-Pick type C (NPC) models, a neurodegenerative disease characterized by cholesterol accumulation in lysosomes, promotes a cholesterol-lowering effect in a TFEB-dependent manner. Thus, c-Abl is a TFEB regulator that mediates its tyrosine phosphorylation, and the inhibition of c-Abl activates TFEB promoting cholesterol clearance in NPC models.